Better Health for All

BB Biotech invests 100% of its assets in the healthcare sector, specifically in biotechnology companies developing novel drugs and therapies for unmet medical needs.

Its portfolio companies received multiple new drug approvals in 2024, including Casgevy for beta thalassemia and severe sickle cell disease, Nexletol for cardiovascular risk reduction, mResvia for RSV infection, Vyvgart Hytrulo for chronic inflammatory demyelinating polyneuropathy, Axatilimab for graft-versus-host disease, Crenessity for congenital adrenal hyperplasia, Tryngolza for familial chylomicronemia syndrome, and Alyftrek for Cystic fibrosis. The company has maintained 0% revenue from controversial business segments such as weapons, thermal coal, tobacco, adult entertainment, gambling, and palm oil since its founding in 1993. As an investment company, 100% of its capital allocation is directed towards health improvement.

Fair Money & Economic Opportunity

BB Biotech AG is an investment company focused on the biotechnology sector, not a financial institution that offers lending, insurance, or deposit services to consumers.

The provided articles consistently state that data related to 'Fair Money & Economic Opportunity' metrics, such as underserved client share, pricing fairness, exploitative fees, or inclusion initiatives, is not applicable to the company's core business. Therefore, all KPIs are scored as 0, indicating that the company does not operate in the consumer financial services sector relevant to this ethical value.

Fair Pay & Worker Respect

The company reports no work-related fatalities or incidents. A salary analysis conducted in August 2023 using the federal government's standard software ("Logib") identified no gender effect.

The employee turnover rate was 2.90% in 2021. Furthermore, no complaints or reports of discrimination have been received via the whistleblowing system. All employees are on permanent contracts.

Fair Trade & Ethical Sourcing

BB Biotech AG is an investment company, and the provided articles primarily detail its ESG integration and exclusion criteria for its investment portfolio, rather than its own operational supply chain. There is no specific, quantifiable evidence regarding the company's direct procurement practices, such as the percentage of fair-trade certified spend, supplier audit frequencies, instances of forced or child labor in its own supply chain, traceability coverage, remediation speed for its own suppliers, ethical clauses in its supplier contracts, or the share of spend on high-risk materials. While the company states a preference for local suppliers and pre-qualifies them for compliance

, no specific metrics are provided to score against the rubric's KPIs.

No War, No Weapons

BB Biotech maintains a 0% revenue threshold for the exclusion of companies involved in controversial weapons

and a 10% revenue threshold for conventional weapons from its investment portfolio . As of December 2023, its portfolio had 0 companies involved in either category , indicating a clear corporate ban on military sales in its investments. These ethical red lines are codified in its policy . Bellevue Asset Management, BB Biotech's investment manager, updates an exclusion list quarterly , which comprises nearly 900 issuers excluded from all investment universes . Bellevue Asset Management is also committed to complying with the UN Guiding Principles for Business and Human Rights and excludes companies that seriously contravene these principles .

Planet-Friendly Business

BB Biotech AG and its investment manager, Bellevue Asset Management, have a net-zero carbon emissions target by 2050

and aim to reduce CO2 emissions per employee by 30% by 2030, but these targets are not stated as SBTi-validated. The company offsets 100% of its CO2 emissions through high-quality climate projects in Switzerland, achieving "Gold certificate" status from Swiss Climate for the fifth consecutive year. BB Biotech has considered TCFD recommendations for the second consecutive year and is working to identify and assess climate-related risks.

Safe & Smart Tech

The company retains contract-related personal data for ten years beyond the termination of the contractual relationship.

It processes personal data in accordance with the Swiss Data Protection Act (FADP) and is committed to transparency under the EU Sustainable Finance Disclosure Regulation (SFDR) , as well as other legal and regulatory obligations in Switzerland and abroad. All Bellevue employees complete annual e-learning modules in cybersecurity. The company states it takes appropriate technical and organizational security measures to protect personal data from unauthorized access and misuse, with no documented incidents. Users are provided with industry-standard data protection rights, including the right to revoke consent, access, rectify, erase, restrict processing, object, and data portability.

Zero Waste & Sustainable Products

The company has implemented several waste reduction initiatives, including waste collection and recycling systems for materials like cardboard, PET, glass, paper, batteries, and IT equipment across all office locations.

Measures are in place to reduce paper consumption, such as using notebooks and tablets for presentations and video calls. The company also uses water filtering devices to reduce PET bottle consumption and washable dishes instead of disposables. For hazardous waste, systems are established to collect and recycle batteries and IT equipment, ensuring waste is separated and disposed of properly. There have been no reported waste disposal violations in 2023 or 2024.